|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (5Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
The big shareholder groups in DiaMedica Therapeutics Inc. ( NASDAQ:DMAC ) have power over the company. Generally...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical Company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S. Food & Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application. The Company plans to proceed with a pivotal Phase 2/3 study of DM199 (recombinant human tissue kallikrein-1or KLK1) for the treatment of patients with Acute Ischemic Stroke (AIS).
NEW YORK, NY / ACCESSWIRE / May 6, 2021 / DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 8:00 AM Eastern Time.